Unknown

Dataset Information

0

Risks of Lynch syndrome cancers for MSH6 mutation carriers.


ABSTRACT:

Background

Germline mutations in MSH6 account for 10%-20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations. Because there have been only a few studies of mutation carriers, their cancer risks are uncertain.

Methods

We identified 113 families of MSH6 mutation carriers from five countries that we ascertained through family cancer clinics and population-based cancer registries. Mutation status, sex, age, and histories of cancer, polypectomy, and hysterectomy were sought from 3104 of their relatives. Age-specific cumulative risks for carriers and hazard ratios (HRs) for cancer risks of carriers, compared with those of the general population of the same country, were estimated by use of a modified segregation analysis with appropriate conditioning depending on ascertainment.

Results

For MSH6 mutation carriers, the estimated cumulative risks to ages 70 and 80 years, respectively, were as follows: for colorectal cancer, 22% (95% confidence interval [CI] = 14% to 32%) and 44% (95% CI = 28% to 62%) for men and 10% (95% CI = 5% to 17%) and 20% (95% CI = 11% to 35%) for women; for endometrial cancer, 26% (95% CI = 18% to 36%) and 44% (95% CI = 30% to 58%); and for any cancer associated with Lynch syndrome, 24% (95% CI = 16% to 37%) and 47% (95% CI = 32% to 66%) for men and 40% (95% CI = 32% to 52%) and 65% (95% CI = 53% to 78%) for women. Compared with incidence for the general population, MSH6 mutation carriers had an eightfold increased incidence of colorectal cancer (HR = 7.6, 95% CI = 5.4 to 10.8), which was independent of sex and age. Women who were MSH6 mutation carriers had a 26-fold increased incidence of endometrial cancer (HR = 25.5, 95% CI = 16.8 to 38.7) and a sixfold increased incidence of other cancers associated with Lynch syndrome (HR = 6.0, 95% CI = 3.4 to 10.7).

Conclusion

We have obtained precise and accurate estimates of both absolute and relative cancer risks for MSH6 mutation carriers.

SUBMITTER: Baglietto L 

PROVIDER: S-EPMC2815724 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Risks of Lynch syndrome cancers for MSH6 mutation carriers.

Baglietto Laura L   Lindor Noralane M NM   Dowty James G JG   White Darren M DM   Wagner Anja A   Gomez Garcia Encarna B EB   Vriends Annette H J T AH   Cartwright Nicola R NR   Barnetson Rebecca A RA   Farrington Susan M SM   Tenesa Albert A   Hampel Heather H   Buchanan Daniel D   Arnold Sven S   Young Joanne J   Walsh Michael D MD   Jass Jeremy J   Macrae Finlay F   Antill Yoland Y   Winship Ingrid M IM   Giles Graham G GG   Goldblatt Jack J   Parry Susan S   Suthers Graeme G   Leggett Barbara B   Butz Malinda M   Aronson Melyssa M   Poynter Jenny N JN   Baron John A JA   Le Marchand Loic L   Haile Robert R   Gallinger Steve S   Hopper John L JL   Potter John J   de la Chapelle Albert A   Vasen Hans F HF   Dunlop Malcolm G MG   Thibodeau Stephen N SN   Jenkins Mark A MA  

Journal of the National Cancer Institute 20091222 3


<h4>Background</h4>Germline mutations in MSH6 account for 10%-20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations. Because there have been only a few studies of mutation carriers, their cancer risks are uncertain.<h4>Methods</h4>We identified 113 families of MSH6 mutation carriers from five countries that we ascertained through family cancer clinics and population-based cancer registries. Mutation status, sex, age, and histories of cancer, polypectomy  ...[more]

Similar Datasets

| S-EPMC2976029 | biostudies-literature
| S-EPMC7410789 | biostudies-literature
| S-EPMC3172927 | biostudies-literature
| S-EPMC4234633 | biostudies-literature
| S-EPMC3275504 | biostudies-literature
| S-EPMC3576323 | biostudies-literature
| S-EPMC5115949 | biostudies-literature
| S-EPMC5454912 | biostudies-literature
| S-EPMC2890527 | biostudies-literature
| S-EPMC5453435 | biostudies-literature